Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Ginkgo’s financial condition, capital markets activity, governance developments, and material events related to its biological product manufacturing and cell engineering platform.
Recent DNA SEC filings include multiple Forms 8-K. These current reports cover topics such as quarterly financial results, entry into a Sales Agreement for potential at-the-market offerings of Class A common stock, and corporate governance matters, including changes in executive responsibilities and the preliminary approval of a settlement of stockholder derivative actions. Each 8-K also confirms that Ginkgo’s Class A common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol DNA.
Investors reviewing Ginkgo Bioworks’ filings can use this page to locate quarterly earnings press releases furnished on Form 8-K, agreements related to equity issuance, and descriptions of legal or governance developments. Over time, the broader filing history may also include annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy statements that discuss topics such as business segments, risk factors, and corporate governance practices.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points of lengthy filings. Instead of reading entire documents line by line, users can quickly see the main themes, then drill into the original forms for details about Ginkgo Bioworks’ cell engineering and biosecurity activities, capital structure, and other disclosed matters.
DNA filing reports notices under Rule 144 to sell Class A shares. The filing lists two reported transactions by Austin Che of 2,200 Class A shares on 01/07/2026 and 02/04/2026, and earlier restricted stock vesting entries dated 10/18/2022 (888 shares) and 10/20/2022 (1,312 shares).
The entries identify Fidelity Brokerage Services LLC and include per-transaction numeric figures (2200) and associated monetary figures shown in the excerpt. This notice-style filing documents planned or reported dispositions; timing and cash-flow treatment are as stated in the entries.
Ginkgo Bioworks Holdings, Inc. entered into a Stock Purchase Agreement under which its wholly owned subsidiary will transfer all issued and outstanding equity of Ginkgo Biosecurity, LLC to Tower Biosecurity, Inc. This business represents substantially all of Ginkgo’s Biosecurity segment operations.
In return, Tower Biosecurity will issue shares of its common stock to Ginkgo’s subsidiary, equal to approximately 20% of Tower’s fully diluted equity. The transaction is expected to close in the first half of 2026, subject to customary closing conditions.
Ginkgo Bioworks Holdings reported 2025 revenue of $170.2 million, down from $227.0 million in 2024, as both cell engineering and biosecurity revenue declined. The company’s net loss narrowed to $312.8 million from $547.0 million, helped by large reductions in research and development and general and administrative expenses.
R&D spending fell to $243.8 million and G&A to $183.3 million, reflecting a restructuring begun in 2024, lower headcount and reduced facilities and professional costs. Adjusted EBITDA improved to a loss of $167.0 million from a loss of $293.3 million, showing progress but continued heavy cash burn.
Biosecurity service revenue declined to $37.4 million on weaker government work, while new cell engineering tools such as Datapoints and automation systems drove higher "cost of other revenue" as those offerings scaled. The company ended 2025 with $167.2 million in cash and equivalents and $255.4 million in marketable securities and believes this liquidity will fund operations for at least 12 months.
Ginkgo Bioworks Holdings, Inc. reported weaker 2025 revenue alongside significantly reduced losses and a major strategic shift. Total revenue for 2025 was $170.2 million, down from $227.0 million (a 25% decline), with Cell Engineering revenue falling to $132.7 million and Biosecurity revenue to $37.4 million. Despite this, the GAAP net loss narrowed sharply to $(312.8) million from $(547.0) million, and Adjusted EBITDA improved to $(167.0) million from $(293.3) million, reflecting lower operating expenses and restructuring benefits.
The company ended 2025 with $423 million in cash, cash equivalents and marketable securities, down from higher prior-year levels, and guided for 2026 total cash burn of $(150)–$(125) million. Ginkgo plans to divest its non‑core biosecurity business to investors in exchange for a minority equity stake, turning it into a standalone private company, while refocusing the business on autonomous labs. Management highlighted expansion of its frontier autonomous lab in Boston, new collaboration results with OpenAI showing a 40% improvement in cell‑free protein synthesis, and a $47 million autonomous lab contract with Pacific Northwest National Laboratory as key proof points for the new strategy.
Ginkgo Bioworks Holdings, Inc. (DNA) received an amended Schedule 13G/A from Baillie Gifford & Co, a Scotland-based investment adviser, reporting its ownership in the company’s Class A common stock as of 12/31/2025.
Baillie Gifford reports beneficial ownership of 2,391,649 Class A shares, representing 4.93% of the class. It has sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Ginkgo Bioworks.
Form 144 discloses that holder Austin Che intends to sell 2,200 Class A shares through Fidelity Brokerage Services LLC on or about 02/04/2026 on the NYSE, with an aggregate market value of 19360.00. The issuer has 48,523,595 Class A shares outstanding.
The shares to be sold were acquired via restricted stock vesting from the issuer on 10/18/2022 (105 shares) and 10/19/2022 (2,095 shares), both as compensation. Over the past three months, Che sold 2,200 Class A shares on each of 11/12/2025, 12/10/2025, and 01/07/2026, for gross proceeds of 18700.00, 20988.00, and 20152.00, respectively.
Ginkgo Bioworks Holdings, Inc. Chief Financial Officer Steven P. Coen reported RSU vesting and a small share sale. On January 16, 2026, RSUs covering 587, 156, and 1,062 units were converted into the same number of Class A common shares at an exercise price of $0 per share, reflecting equity awards that had been vesting over time. After these conversions, he held 9,293 Class A shares directly. On January 20, 2026, he sold 972 Class A shares at $8.917 per share, leaving him with 8,321 shares. According to the footnotes, the sale was made to cover tax withholding obligations related to the vesting of restricted stock and RSUs and did not represent a discretionary trade.
Ginkgo Bioworks Holdings (symbol DNA) filed a notice of proposed sales of restricted stock under Rule 144. The filing covers a planned sale of 972 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 8,667.23 and 48,523,595 Class A shares outstanding.
The 972 Class A shares were acquired on 01/16/2026 through restricted stock vesting from the issuer as compensation, with payment dated 01/16/2026. The notice also discloses that Steven Coen previously sold 736 Class A shares on 12/15/2025 for gross proceeds of 6,540.02.
A holder of Class A shares of DNA has filed a notice of proposed sale under Rule 144. The filing covers 2,200 Class A shares to be sold through Fidelity Brokerage Services LLC, with an indicated aggregate market value of 20,152.00. The shares are listed on the NYSE, and the approximate sale date given is 01/07/2026. These 2,200 shares were acquired on 10/19/2022 through restricted stock vesting from the issuer as compensation. The filing notes that there are 48,523,595 Class A shares outstanding. Over the prior three months, the same seller, Austin Che, reported three separate sales of 2,200 Class A shares each, with gross proceeds of 33,462.00, 18,700.00, and 20,988.00.
Ginkgo Bioworks Holdings, Inc. reported a leadership transition in its operating roles. Effective January 1, 2026, co‑founder Dr. Reshma Shetty will transition her Chief Operating Officer responsibilities to Chief Executive Officer Dr. Jason Kelly and executive Jennifer Wipf. Dr. Shetty will remain President, continue serving on the Board of Directors, and focus on expanding and using the company’s autonomous lab to deliver cell engineering service offerings, while Dr. Kelly will take on the principal operating officer policymaking duties.
Jennifer Wipf, previously Chief Commercial Officer and General Manager, Discovery Solutions and Manufacturing, will oversee operations functions such as day‑to‑day commercial operations, procurement, deployment, facilities and real estate, and people operations, reporting to Dr. Kelly. The changes keep Dr. Shetty in a substantial policymaking role while formalizing broader operating responsibilities for Dr. Kelly and Ms. Wipf.